Alpha 2.0
Login Register
» Authors » Breanna Essoi

Breanna Essoi

Explore the profile of Breanna Essoi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 12
Citations 44
Followers 0
Related Specialties
Pharmacology
Pulmonary Medicine
Pharmacy
Top 10 Co-Authors
John White
Alyssa Goolsby Hunter
Beth Hahn
Riju Ray
Richard H Stanford
Valery Walker
Carolyn Martin
Jessica L Abel
Kasem S Akhras
Stephanie Korrer
Published In
J Manag Care Spec Pharm
Pulm Ther
Patient Prefer Adherence
Multidiscip Respir Med
COPD
Affiliations
Soon will be listed here.
Recent Articles
1.
Reasons for switching oral antipsychotic medications and related patterns of care and costs in patients with schizophrenia initiating monotherapy treatment: Claims-linked chart study
Fee R, Webb N, Dick L, White J, Essoi B, Walker V, et al.
J Manag Care Spec Pharm . 2024 May; 30(7):698-709. PMID: 38717043
Background: Antipsychotic switching is frequent in schizophrenia and is associated with poor clinical outcomes, increased health care resource utilization (HCRU), and increased health care costs. Research describing the reasons for...
2.
Patterns of care and costs of switching oral antipsychotic medications in patients with schizophrenia initiating monotherapy treatment: A US claims analysis
Fee R, Webb N, Dick L, White J, Essoi B, Walker V, et al.
J Manag Care Spec Pharm . 2024 Apr; 30(6):560-571. PMID: 38591754
Background: Antipsychotic medications are the mainstay of schizophrenia therapy but may need to be changed over the course of a patient's illness to achieve the desired therapeutic goals or minimize...
3.
Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy
Moretz C, Hahn B, White J, Hunter A, Essoi B, Elliott C, et al.
Int J Chron Obstruct Pulmon Dis . 2020 Nov; 15:2715-2725. PMID: 33149569
Background: Long-acting muscarinic antagonist/long-acting β-agonist (LAMA/LABA) provide greater improvements in lung function and symptoms than inhaled corticosteroid (ICS)/LABA in patients with chronic obstructive pulmonary disease (COPD). This study evaluated symptom...
4.
The Identification and Cost of Acute Chronic Obstructive Pulmonary Disease Exacerbations in a United States Population Healthcare Claims Database
Stanford R, Engel-Nitz N, Bancroft T, Essoi B
COPD . 2020 Sep; 17(5):499-508. PMID: 32962447
Almost half of chronic obstructive pulmonary disease (COPD) exacerbations are estimated to be inaccurately reported by patients, inconsistently recorded in medical records, or not measured due to coding errors inherent...
5.
Comprehensive assessment of patients with irritable bowel syndrome with constipation and chronic idiopathic constipation using deterministically linked administrative claims and patient-reported data: the Chronic Constipation and IBS-C Treatment and...
Taylor D, Abel J, Martin C, Doshi J, Essoi B, Korrer S, et al.
J Med Econ . 2020 Jul; 23(10):1072-1083. PMID: 32696684
Aims: To characterize a US population of patients with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) using CONTOR, a real-world longitudinal research platform that deterministically linked...
6.
Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study
Hahn B, Stanford R, Hunter A, Essoi B, White J, Ray R
Pulm Ther . 2020 Feb; 5(1):69-80. PMID: 32026428
Introduction: Symptom burden in inadequately controlled chronic obstructive pulmonary disease (COPD) considerably impacts quality of life, healthcare resource utilization (HCRU) and associated costs. This claims-linked cross-sectional survey study assessed symptom...
7.
Predictors of Symptom Burden in Patients with COPD on LAMA Monotherapy: Multivariable Analysis of a Claims-Linked Survey Study
Hahn B, Stanford R, Hunter A, White J, Essoi B, Ray R
Pulm Ther . 2020 Feb; 5(2):179-190. PMID: 32026410
Introduction: Many patients with chronic obstructive pulmonary disease (COPD) prescribed long-acting muscarinic antagonist (LAMA) monotherapy remain symptomatic. This multivariable analysis of a previously reported claims-linked, cross-sectional survey assessed symptom burden...
8.
Classification of Patients with COPD on LAMA Monotherapy Using the GOLD Criteria: Analysis of a Claims-Linked Patient Survey Study
Ray R, Hahn B, Stanford R, White J, Essoi B, Hunter A
Pulm Ther . 2020 Feb; 5(2):191-200. PMID: 32026409
Introduction: To address the burden of chronic obstructive pulmonary disease (COPD), the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends treatment according to classification of patients by symptom severity...
9.
Observational vignette study to examine patient and healthcare provider perceived impact of asthma-related exacerbations in the US
Johnson P, Bell C, White J, Essoi B, Nelsen L, Averell C
Multidiscip Respir Med . 2019 Nov; 14:32. PMID: 31700624
Background: Little is known about how patients and healthcare providers (HCPs) perceive the impact of asthma-related exacerbations. This study examined the impact of asthma-related exacerbations on patients' lives from these...
10.
The Impact of Stool Consistency on Bowel Movement Satisfaction in Patients With IBS-C or CIC Treated With Linaclotide or Other Medications: Real-World Evidence From the CONTOR Study
Taylor D, Abel J, Doshi J, Martin C, Hunter A, Essoi B, et al.
J Clin Gastroenterol . 2019 Jul; 53(10):737-743. PMID: 31361710
Goals: This study aimed to characterize the impact of stool consistency on patient-reported bowel movement (BM) satisfaction in patients with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation,...